美股详情

本页面由Tiger Fintech (Singapore) Pte. Ltd.提供服务

RayzeBio, Inc.

62.49

0.0000

成交量：- -

成交额：1,733.29万

市值：37.44亿

市盈率：-7.13

高：62.49

开：62.49

低：62.49

收：62.49

52周最高：62.51

52周最低：17.95

股本：5,991.95万

流通股本：3,481.97万

量比：- -

换手率：- -

股息：- -

股息率：- -

每股收益(TTM):-8.7663

每股收益(LYR):-19.8964

净资产收益率：--

总资产收益率：--

市净率：6.51

市盈率(LYR):-3.14

数据加载中...

总览公司新闻公告

百时美施贵宝重获RayzeBio管线产品在大中华区市场独家开发和商业化权利

TCE按下自免加速键

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/stock/RYZB/news"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"RYZB","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"RYZB\",,,,,undefined,":{"symbol":"RYZB","market":"US","secType":"STK","nameCN":"RayzeBio, Inc.","latestPrice":62.49,"timestamp":1708722000000,"preClose":62.49,"halted":3,"volume":0,"delay":0,"floatShares":34819731,"shares":59919502,"eps":-8.766259,"marketStatus":"停牌","change":0,"latestTime":"08-08 06:14:10 EDT","open":62.49,"high":62.49,"low":62.49,"amount":17332947.2238,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-8.766259,"tradingStatus":1,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1754659800000},"marketStatusCode":1,"adr":0,"listingDate":1694750400000,"exchange":"NASDAQ","adjPreClose":62.49,"volumeRatio":0},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"RYZB\",,,,,undefined,":{"symbol":"RYZB","floatShares":34819731,"roa":"--","roe":"--","lyrEps":-19.896435,"shares":59919502,"dividePrice":0,"high":62.49,"amplitude":0,"preClose":62.49,"low":62.49,"week52Low":17.95,"pbRate":"6.51","week52High":62.51,"institutionHeld":0,"latestPrice":62.49,"eps":-8.766259,"divideRate":0,"volume":0,"delay":0,"ttmEps":-8.766259,"open":62.49,"prevYearClose":62.17},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/RYZB\",params:#limit:5,,,undefined,":[{"market":"US","date":"2024-02-27","symbol":"RYZB","reason":null,"defaultRemindTime":1709044200000,"announcedDate":"2024-02-23","type":"delisting","dateTimestamp":1709010000000}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"RYZB\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"RYZB\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.25,"buy":0.5,"hold":0.25,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.5,"analysts":4,"updateTime":1703998800000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/RYZB\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"RYZB","date":"2024-02-23","current":-58.953302,"percent":0.150538,"low":-59.59825,"twenty":-58.87593,"median":-24.211616,"eighty":-17.264309,"high":-1.756766,"avg":-35.263311,"sd":19.858488,"marketCap":3743770484},"quantilePoints":[{"date":"2023-09-15","current":-15.14118,"twenty":-15.14118,"median":-15.14118,"eighty":-15.14118,"marketCap":995683968},{"date":"2023-09-20","current":-18.514298,"twenty":-19.387439,"median":-18.514298,"eighty":-16.490427,"marketCap":1217500229},{"date":"2023-09-27","current":-15.57018,"twenty":-18.805345,"median":-15.830944,"eighty":-15.48438,"marketCap":1023895013},{"date":"2023-10-06","current":-16.874003,"twenty":-18.578227,"median":-16.874003,"eighty":-15.726638,"marketCap":1109634466},{"date":"2023-10-13","current":-17.244121,"twenty":-18.019686,"median":-17.059062,"eighty":-16.037874,"marketCap":1133973408},{"date":"2023-10-20","current":-16.402945,"twenty":-18.125675,"median":-17.244121,"eighty":-16.312098,"marketCap":1078657632},{"date":"2023-10-27","current":-15.940297,"twenty":-18.051651,"median":-17.033827,"eighty":-16.175827,"marketCap":1048233955},{"date":"2023-11-03","current":-17.277768,"twenty":-17.762286,"median":-16.941298,"eighty":-16.128721,"marketCap":1136186039},{"date":"2023-11-10","current":-16.815121,"twenty":-18.272039,"median":-17.138974,"eighty":-16.290227,"marketCap":1105762362},{"date":"2023-11-17","current":-1.756766,"twenty":-18.272039,"median":-17.033827,"eighty":-16.128721,"marketCap":111561655},{"date":"2023-11-24","current":-21.61684,"twenty":-18.49411,"median":-17.244121,"eighty":-16.204427,"marketCap":1372755790},{"date":"2023-12-01","current":-22.532088,"twenty":-19.070104,"median":-17.33665,"eighty":-16.335651,"marketCap":1430877707},{"date":"2023-12-08","current":-24.994766,"twenty":-21.324338,"median":-17.555357,"eighty":-16.402945,"marketCap":1587267607},{"date":"2023-12-15","current":-25.098557,"twenty":-21.656469,"median":-17.929699,"eighty":-16.719227,"marketCap":1593858753},{"date":"2023-12-22","current":-26.372356,"twenty":-22.762315,"median":-18.23671,"eighty":-16.811756,"marketCap":1674750080},{"date":"2023-12-29","current":-59.271474,"twenty":-24.09084,"median":-18.463828,"eighty":-16.818486,"marketCap":3763975660},{"date":"2024-01-05","current":-59.434862,"twenty":-24.90041,"median":-18.674121,"eighty":-16.823533,"marketCap":3774351464},{"date":"2024-01-12","current":-59.406029,"twenty":-25.381623,"median":-19.033195,"eighty":-16.840356,"marketCap":3772520440},{"date":"2024-01-19","current":-58.415476,"twenty":-34.75867,"median":-20.538426,"eighty":-16.867274,"marketCap":3709616368},{"date":"2024-01-26","current":-58.57588,"twenty":-58.438121,"median":-21.437564,"eighty":-16.927839,"marketCap":3719802684},{"date":"2024-02-02","current":-58.623058,"twenty":-58.579654,"median":-21.715913,"eighty":-17.008592,"marketCap":3722798659},{"date":"2024-02-09","current":-58.755155,"twenty":-58.615509,"median":-22.532088,"eighty":-17.032145,"marketCap":3731187389},{"date":"2024-02-16","current":-58.887253,"twenty":-58.764591,"median":-23.805886,"eighty":-17.202062,"marketCap":3739576119},{"date":"2024-02-23","current":-58.953302,"twenty":-58.87593,"median":-24.211616,"eighty":-17.264309,"marketCap":3743770484}],"updateTime":1754647586150},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"RYZB\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2492025451","title":"百时美施贵宝重获RayzeBio管线产品在大中华区市场独家开发和商业化权利","url":"https://stock-news.laohu8.com/highlight/detail?id=2492025451","media":"界面","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492025451?lang=zh_cn&edition=fundamental","pubTime":"2024-12-20 10:50","pubTimestamp":1734663022,"startTime":"0","endTime":"0","summary":"12月19日，百时美施贵宝宣布，公司已与艾博兹医药达成了一项协议，百时美施贵宝重新取得了在大中华区开发和商业化ABZ-706（相当于RYZ801）的独家权利，该管线产品用于针对GPC3靶点的肝细胞癌治疗，同时也终止了与艾博兹之前签订的一项广泛授权协议，该协议授予艾博兹对RayzeBio至多四个管线产品（包括ABZ-706）在这些市场的开发和商业化权利。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241220105022ab85db0d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241220105022ab85db0d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1093756168.USD","IE00B2B36J28.USD","LU1868837136.USD","IE0009355771.USD","LU1868836914.USD","LU0306807586.USD","LU1718418525.SGD","LU1868837300.USD","BK4532","LU1323610961.USD","LU1670711040.USD","IE00BJT1NW94.SGD","LU1291159041.SGD","IE00BFTCPJ56.SGD","LU0321505868.SGD","RYZB","BK4588","LU0114720955.EUR","IE00BJJMRZ35.SGD","LU1670710661.SGD","LU2360032135.SGD","LU1032466523.USD","LU0456855351.SGD","BMY","BK4139","LU1074936037.SGD","LU0985481810.HKD","LU0225284248.USD","LU0225771236.USD","LU1571399168.USD","LU1261432733.SGD","LU0096364046.USD","LU1868836757.USD","LU1868836591.USD","LU0868494617.USD","LU2242652126.USD","LU2133065610.SGD","IE00BSNM7G36.USD","LU1430594728.SGD","LU1670710588.SGD","BK4585","BK4534","BK4559","LU0061475181.USD","LU0306806265.USD","LU0882574055.USD","LU0237698245.USD","BK4581","LU1093756325.SGD","IE0002141913.USD"],"gpt_icon":0},{"id":"2492279190","title":"TCE按下自免加速键","url":"https://stock-news.laohu8.com/highlight/detail?id=2492279190","media":"蓝鲸财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492279190?lang=zh_cn&edition=fundamental","pubTime":"2024-12-19 11:51","pubTimestamp":1734580293,"startTime":"0","endTime":"0","summary":"TCE在自免领域按下加速键。过去一年，同润生物、恩沐生物相继达成了高总额的首付款交易，让自免领域的TCE交易成为国产创新药出海的最大热点之一。12月16日，Candid Therapeutics在一天之内，实现了三连击，分别与诺纳生物、岸迈生物、Ab Studio三家企业达成TCE合作。目前来看，TCE在自免领域的热度，有望进一步升温。Candid能否如愿不得而知，但其只是TCE在自免市场加速发展的一个缩影。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/247308","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["SLE","BK4139","RYZB","BK4077"],"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":2,"code":"91000000","status":"200"}]}}